Jubilant Therapeutics Inc.
- Home
- Companies
- Jubilant Therapeutics Inc.
- Products
- Model PRMT5 - Novel Small Molecule
Model PRMT5 - Novel Small Molecule
Strong scientific and clinical rationale for novel small molecule PRMT5 inhibitor.
Most popular related searches
- PRMT5 is the predominant Type II PRMT that is responsible for symmetric dimethylation of arginine (SDMA) on histone and non-histone substrates
- PRMT5 is highly overexpressed in many human cancers
- Glioblastoma (GBM) with splicing dysregulation is selectively sensitive to inhibition of PRMT5
- PRMT5 inhibition impairs the removal of detained introns leading to modulation of proliferation specific genes
- GBM specific key tumor suppressor is silenced by PRMT5 leading to poor prognosis
- Potential for patient stratification: targeting tumors with high CLNS1A/RIOK1 ratio
- Brain-penetrant PRMT5 inhibitor to address the unmet medical need in treating GBM
- Potential use in other cancers where PRMT5 is over expressed (lymphoma, pancreas, SCLC, etc) and in cancers with spliceosome dysregulation